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ABSTRACT 
 
   At present radiation therapy and radical prostatectomy are considered to be the treatment of choice 
for clinical T1-T2 prostate cancer. In a more advanced stage of the disease (T3) 10-year overall 
survival is observed in approximately 40% of patients treated with conventional radiotherapy. So far 
only a few methods for improving the efficacy of radiotherapy have been introduced. One of them is 
a three-dimensional conformal radiotherapy with 3 dimensional treatment planning. These novel me-
thods make it possible to escalate the dose to the target and protect healthy tissue at the same time. 
The optimal volume of irradiation, total dose, fraction dose, techniques of radiotherapy, and the end 
points used during the follow-up are open to debate. In recent years a few clinical trials involving 
hormonal therapy and radiotherapy have been carried out. The most important of these are: RTOG 
8307, RTOG 8610, RTOG 9202, and EORTC 22863.  
   In the RTOG 8307 trial the comparison of outcomes of a combined treatment with a matched-control 
group of patients treated by radiotherapy alone has shown that adding hormonal therapy to radio-
therapy resulted in a better outcome. Another trials RTOG 8531 and RTOG 8610 produced benefit 
due to the implementation of hormonal therapy in radiotherapy. The EORTC trial No. 22863 showed 
improvement in the 5-year overall survival when hormonal therapy after the completion of radiotherapy 
was continued for 3 years in the investigational arm. The RTOG 9202 study indicated benefit obtained 
from 2 years of adjuvant hormonal therapy.  
   The results of these trials have had a substantial impact on the management of locally advanced 
prostate cancer, but there are still questions that have to be answered. There is no doubt that hormo-
nal therapy is an important component of the management of locally advanced prostate cancer. Still 
the optimal combination of drugs and the timing of such treatment remains controversial. Considering 
the potential side effects of a combined treatment on the quality of life of patients and care costs, 
additional properly designed randomised trials are needed to identify the subgroup of patients who will 
obtain the greatest benefit. Currently, it can be concluded that in the group of patients with a high risk 
of relapse by adding hormonal therapy to radiotherapy the outcome of treatment in patients with 
prostate cancer has improved.  
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INTRODUCTION 
 
   From the urologist’s point of view radical 
prostatectomy is a standard method 
of treatment in localized prostate cancer 
[1,2]. However, surgery is generally not an 
adequate mode of treatment for the ad-
vanced stage of the disease. In patients 
with locally prostate cancer the external 
beam radiation therapy, especially, 
3-dimensional conformal radiotherapy 
(3D CRT) is a treatment which can provide 
the same results as surgery. Additionally, 
3D CRT reduces side effects [3,4,5]. 
The third mode of treatment in patients 
with prostate cancer is hormonal therapy. 
This modality alone has generally only 
a palliative effect but in combination with 
radiotherapy it may lead to a cure or in-
fluence the prolongation of survival in the 
majority of patients. Based on the earliest 
studies carried by Huggins and Hodges 
[6], the male hormones are known to pro-
mote the growth of both prostate gland 
and cancer cells. The main androgen in-
volved in the stimulation of growth of the 
prostate and cancer cells is dihydrotesto-
sterone (DHT). Generally, hormonal the-
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rapy refers to any treatment that reduces 
the level of biological activity of male hor-
mones. Two mechanisms involved in an-
drogen suppression strategy of treatment 
are distinguished. The first leads to elimi-
nating the production of testosterone 
in testis by surgical castration (bilateral 
orchiectomy) or by chemical castration 
(LHRH analog). The latter mechanism gai-
ned popularity during the last few decades 
when LHRH analogs (Lutenazing Hormo-
ne Realizing Hormone) were introduced 
into clinical practice. However, the effects 
of LHRH agonists are limited to the blo-
ckage of testicular androgens, similar 
to surgical castration [7]. They cause 
the pituitary desensitisation and inhibition 
of sex steroid production. Agonists do not 
influence the production of dehydroepian-
drosterone (DHEA) and dehydroepian-
drosterone-sulfate (DHEA-S) by adrenal 
glands. Another group of drugs which is 
very popular in the treatment of patients 
with prostate cancer is antiandrogen me-
dication. Mechanism of action of this class 
of drugs involves blocking of the intra-
cellular androgen receptor, which is loca-
ted in the tumour cell [8]. Currently, two 
groups are in clinical usage: steroidal 
(cyproterone acetate - CPA, medroxypro-
gesterone acetate - MPA) and nonsteroi-
dal (flutamide and its metabolites such 
nilutamide and bicalutamide - Casodex).  
   Steroidal antiandrogens have a proge-
sterone-like effect, which causes a decree-
ase in the release of LH by the hypo-
physis. The non-steroidal antiandrogens 
block the binding of dihydrotestosterone 
with the intracellular androgens receptor.  
   There is general agreement that sym-
ptomatic men with a metastatic disease 
should receive hormonal therapy. Alt-
hough, hormonal therapy for an advanced 
stage of cancer (metastatic) is not a cu-
rative method of treatment, but it may lead 
in some cases to the prolongation 
of the patient’s life and improvement 
of the quality of life [9].  
 
THE POSSIBLE MECHANISM OF IN-
TERACTIONS BETWEEN ANDROGEN 
DEPRESSION AND RADIOTHERAPY 
 
   The idea that the addition of an 
androgen ablation therapy to radiotherapy 
may improve the results of combined 
treatment is based on earlier experience 
in the application of neoadjuvant hormonal 
therapy with surgery [10]. Neoadjuvant 
surgical trials have showed response rates 
(reduction in tumour volume) approaching 
90% when hormonal treatment prior to sur-
gery was applied, with both the prostate 
and the tumour becoming smaller. The re-
sult of such modality leads only to a redu-
ced number of positive postoperative mar-
gins after radical prostatectomy without 
any influence on the patient’s overall survi-
val [11].  
   Androgen deprivation improved the out-
comes of combined treatment as a result 
of local and systemic actions, which are 
represented by hormonal therapy. The me-
chanism of interaction between hormonal 
therapy and radiotherapy has not been 
precisely established, but the following 
areas of interaction can be identified:  
1. Local interactions: 
(a). Androgen deprivation treatment 
leads to the shrinkage in the size 
of the entire enlarged prostate 
gland. It has a very practical 
implication for radiotherapy 
treatment. First, the dimensions 
of fields used in radiotherapy 
could be smaller, which would 
allow for administering a higher 
total dose with the decrease 
in side effects in a healthy tissue 
[12]. Data from numerous papers 
indicate that neoadjuvant hor-
monal therapy result in a sub-
stantial tumour volume reduction 
ranging from 30 to 40 % [13]. 
Substantial prolongation of hor-
monal therapy beyond 6 months 
gives only a slight reduction 
in volume. 
(b). The decrease in the number 
of clonogenic cancer cells due 
to androgen ablation therapy 
should lead to the enhancement 
of radiotherapy effects in the tu-
mour at the same range of doses 
[14]. 
(c). It is known that the tumour of the 
prostate cancer contains mali-
gnant cells which exist in the en-
vironment with a low level of oxy-
gen [15]. Androgen deprivation 
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treatment leads to a decrease 
in the amount of cancer cells 
in the tumour and thus the im-
provement of the blood flow 
could cause enhancement in the 
oxygenation [16].  
(d). Apoptosis induced by hormonal 
therapy involves cancer cells 
in which apoptosis failed to be 
activated by radiotherapy [17]. 
2. Systemic interaction: androgen depri-
vation may prevents subsequent dis-
tant micrometastases [18].  
 
THE MOST IMPORTANT CLINICAL 
TRIALS WHICH ASSESSED COMBINED 
TREATMENT 
 
   One of the first trials, which tried 
to answer the question of the influence 
of additional hormonal therapy on the out-
come of treatment in locally advanced 
prostate was carried out by Zagars et al. 
[19]. According to the trial, radiotherapy 
alone was compared to the radiotherapy 
+ adjuvant hormonal therapy (diethylostil-
bestrol). A 15-year disease-free survival 
(DFS) in the adjuvant estrogen group was 
strikingly and significantly higher than that 
in the radiation-alone group (63% vs. 
35%). However, there was no improve-
ment in the overall survival (OS) because 
of greater intercurrent disease-related 
mortality in patients receiving estrogens. 
   In another trial, RTOG 8307 [20], pa-
tients with stages T2b and T3 were en-
tered into the study and randomised 
to receive megestrol acetate 40 mg three 
times daily, or diethylostilbestrol (DES) 
1 mg three times daily. The treatment 
started 2 months prior to the beginning 
of irradiation and continued through 
the whole course of radiotherapy. It should 
be underlined that the assessment of pre-
treatment PSA in this study was not 
available. Another fact worth underlining is 
that the time of androgen ablation 
treatment was very short lasting only 
4 months.  
   Recently, the outcomes from a few pro-
spective randomised trials have indicated 
that combined treatment (androgen ab-
lation plus radiotherapy) leads to the pro-
longation of overall survival. One of these 
well-documented trials was carried out by 
Pilepich et co-workers [21]. In this trial 
(RTOG 8531) the influence of androgen 
depletion with combination with radiothe-
rapy on results of treatment was evalu-
ated. Patients in this trial were randomised 
to receive radiotherapy alone or radio-
therapy plus adjuvant goserelin acetate 
(LHRH agonist) which was introduced 
in the last week of radiotherapy. The hor-
monal therapy was continued until the pro-
gression of disease occurred, or as long 
as it was tolerated by the patient. 
Radiotherapy fields in the first phase 
of treatment covered of the lymph nodes 
of the pelvis with a dose of 44 – 50 Gy and 
then an additional dose of 20 – 25 Gy 
to the prostate was added. At the me- 
dian follow-up of 4.5 years (range 0.2 
- 9.8 years), the actuarial projections sho-
wed that 84% of patients on the combined-
therapy arm and 71% of those on the RT-
alone arm had no evidence of local 
recurrence (p < 0.0001). The update 
of RTOG trial 85-31 presented in 1999 
with a median follow-up of 5.6 years for all 
patients and 6 years for patients who were 
alive, showed improvement in cause 
specific survival (CSS) in the group of pa-
tients treated with hormonal therapy 
(p = 0.019). 
   In the next RTOG 8610 study carried out 
by Pilepich et al. [22], patients received 
neoadjuvant (2 months) and then, during 
radiotherapy, androgen ablation (goserelin 
+ flutamide) in the investigational arm, 
and radiotherapy alone in the control arm. 
The results of this trial indicated that 
patients in the combined-therapy group 
had a better local control, with 5- and 
8-year failure rates of 25% and 37%, 
respectively, compared with 36% and 49% 
in the RT group (p< 0.002). 
   The results of the well documented 
randomised trial conducted by the EORTC 
22863 came from Europe. The difference 
between this trial and the trials mentioned 
above mainly involved the time duration 
of the androgen depletion therapy. In this 
study reported by Bolla et co-workers [23], 
the results of treatment in the two group 
of patients were compared, whereas, only 
in the investigational arm post radio-
therapy androgen depletion therapy 
(LHRH analog) was continued for 3 years. 
In the first phase of the trial in both arms, 
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hormonal therapy prior to radiotherapy and 
during the irradiation goserelin acetate 
(LHRH analog) and cyproterone acetate 
(150 mg per day/1 month) was employed. 
Patients in both groups received 50 Gy 
of radiation to the pelvis lymph nodes, 
and then an additional dose of 20 Gy 
to the prostate. This report was particularly 
valuable because it incorporated short 
neoadjuvant androgen ablation treatment 
with long-term adjuvant therapy. The re-
sults of the trial indicated that local control 
in the investigational arm (combined treat-
ment) was 97% in comparison with 77% 
in the control arm (radiotherapy alone) 
during the 45 months follow-up. The 5-year 
overall survival in the combined treatment 
arm was 79% vs. 62% in the radiotherapy 
alone group, retrospectively. 
   Another very important study, reported 
by Laverdiere et al. [24], compared 
the following methods of treatment: 
• radiotherapy alone,  
• neoadjuvant combined androgen blo-
ckade (3 months) + radiotherapy, 
• neoadjuvant combined androgen blo-
ckade (3 months) + radiotherapy + ad-
juvant combined androgen blockade 
(10.5 months).  
   Results of this study showed the advan-
tage of neoadjuvant and adjuvant hor-
monal therapy. According to these results 
patients treated with a dose of 64 Gy 
in combined fashion noted 28% of positive 
biopsies compared with 65% treated with 
radiotherapy alone. However, the neoadju-
vant androgen deprivation given 3 months 
before and 6 months after the radiotherapy 
was associated with only 5% rate of posi-
tive biopsies. 
   The data concerning the assessment 
of the influence of combined therapy 
on the outcome of treatment was based 
on the results of observation of 1554 
patients who were entered in to the RTOG 
– 9202 trial conducted by Hanks et al. [25]. 
According to the trial’s protocol all patients 
received goserelin and eulexin 2 months 
before and then during radiotherapy, and 
later, after the completion of radiotherapy, 
were randomised without any further the-
rapy or were administered additional gose-
relin alone for 24 months. This trial sho-
wed some significant improvement in the 
local progression rate (6.2% vs. 13%), 
disease-free survival (54% vs. 34%), 
freedom from distant metastases (11% vs. 
17%), and biochemical control (46% vs. 
21%) in the group long-term hormonally 
treated patients. It should be noted that 
the subset analysis (T3, T4 and T2 with 
Gleason 8-10) showed no significant 
overall survival difference (77% vs. 80%) 
in the period of 5-years. The second 
subset analysis (patients with Gleason 
8-10 versus the group of patients from 
RTOG 85-31 study) indicated therapeutic 
gain due to long-term androgen ablation 
therapy (80% vs. 69% during a 5-year 
follow up).  
   The observation on the addition of hor-
monal therapy to radiotherapy which 
results in a better outcome of treatment 
raises a number of questions: 
1. PSA is the most important indicator 
of the biochemical relapse of radio-
therapy during the follow-up of patients 
with prostate cancer. In prostate can-
cer the introduction of hormonal the-
rapy may lead to a rapid biochemical 
response (decrease of PSA level), 
usually after 2 - 3 months from the be-
ginning of the treatment, which, in the 
phase of follow-up, makes it difficult 
to assess the response of radiothe-
rapy. On the other hand, it should be 
noted that even in the case of unde-
tectable serum PSA level is it uncertain 
that cancer is eradicated [26].  
2. Toxicity: 
Hormonal therapy produces many side 
effects such as gynecomastia, breast 
tenderness, and osteoporosis. Another 
aspect concerns the sexual function, 
which is significantly depressed due 
to hormonal therapy [27]. Another 
interesting issue is the increase in to-
xicity of combined treatment in the bo-
ne (head of femoral bone), especially 
as the androgen suppression treat-
ment caused a higher risk of osteo-
porosis [28, 29]. Combined treatment 
(neoadjuvant and concurrent hormonal 
therapy plus radiotherapy) might lead 
to the decrease in the volume of the 
prostate gland during the course of ra-
diotherapy, bringing more rectal mu-
cosa into the high dose. So far we 
have had no evidence using a multi-
variable analysis that the use of neo-
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adjuvant and concurrent androgen su-
ppression therapy is a significant pre-
dictor of rectal bleeding.  
3. Timing of hormonal therapy: 
The first aspect of this issue is the re-
lative timing of ablation and radiation 
therapy. According to the trials men-
tioned above the minimum time to be-
gin hormonal therapy before radio-
therapy (neoadjuvant) both for external 
beam therapy and brachytherapy 
is approximately 3 months. This is pro-
bably enough to achieve volume redu-
ction of the prostate gland. The second 
issue concerns the duration of hormo-
nal ablation. Currently, this period 
of time is not defined and the optimal 
time probably depends on the risk 
factors of the disease. Generally, 
in a patient with a higher risk of failure 
longer time of hormonal therapy is re-
quired. Patients with an earlier stage 
of the disease may probably benefit 
from short-term hormonal therapy.  
What kind of androgen blockade 
should be preferred (maximum andro-
gen blockade or androgen suppression 
only) in combination with radiotherapy? 
In advanced prostate cancer, the addi-
tion of antiandrogen to androgen su-
ppression by surgery or drugs impro-
ved the 5-year survival by about 2% 
or 3%, depending on whether the ana-
lysis includes or excludes the crypto-
terone. In many trials the control group 
(radiotherapy alone) in case of disease 
progression received androgens abla-
tion. Thus in reality, these trials adder-
ssed the issue of early versus late 
androgen suppression.  
4. Economical aspect of combined treat-
ment: 
For example, in 1993, the Health Care 
Financing Administration spent $ 328 
million alone for LHRH agonist therapy 
[31]. The addition of flutamide to ca-
stration added approximately $ 3,427 
per year to the cost of treatment 
in patients with prostate cancer. 
 
CONCLUSIONS 
 
   On the basis of the data from literature 
it could be concluded that: 
1. Androgen deprivation therapy is easy 
to administer and requires no special 
technology. Neoadjuvant and adjuvant 
androgen deprivation is a standard 
treatment in conjunction with radiation 
therapy in the group of patients with 
a high risk of failure (T3, PSA>20ng/ml, 
Gleason >7). It could be stated that 
the therapeutic gain of combined treat-
ment is probably higher when the com-
bined treatment is applied to patients 
in the higher-risk group.  
2. The optimal timing of the application 
of androgen depletion has still not 
been determined. Currently, approxi-
mately 3 months for neoadjuvant the-
rapy is probably the optimal strategy. 
The best mode of neoadjuvant hormo-
nal therapy is represented by castra-
tion (surgery or chemical), probably 
plus antiandrogen. Adjuvant hormonal 
therapy should be advised in high-risk 
patients, but the duration of this treat-
ment has not been established 
precisely, the probable minimal time 
of treatment should be around 
12 months. Thus far the studies have 
shown that there is survival benefit 
for patients with a more advanced 
disease with a longer androgen 
suppression treatment applied, but 
in the group of lower risk, patients may 
benefit from a short-term hormonal 
therapy.  
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